REFERENCES
- Barisoni L, Kriz W, Mundel P, D'Agati V. The dysregulatedpodocyte phenotype: A novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 1999;10: 51–61
- Shirato I, Hosser H, Kimura K, et al. The development of focal segmental glomerulosclerosis in masugi nephritis is based on progressive podocyte damage. Virchows Arch 1996;429: 255–73
- Wanke R, Wolf E, Brem G, Hermanns W. Role of podocyte damage in the pathogenesis of glomerulosclerosis and tubulointerstitial lesions: Findings in the growth hormone transgenic mouse model of progressive nephropathy. Verh Dtsch Ges Pathol 2001;85: 250–6
- D'Agati VD. Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 2003;23: 117–34
- Kriz W. The pathogenesis of “classic” focal segmental glomerulosclerosis—Lessons from rat models. Nephrol Dial Transplant 2003;18: vi39–44
- Asanuma K, Mundel P. The role of podocytes in glomerular pathobiology. Clin Exp Nephrol 2003;7: 255–9
- Kriz W, Lemley KV. The role of the podocyte in glomerulosclerosis. Curr Opin Nephrol Hypertens 1999;8: 489–97
- Kerjaschki D. Caught flat-footed: Podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 2001;108: 1583–7
- Fukuda A, Chowdhury MA, Venkatareddy MP, et al. Growth-dependent podocyte failure causes glomerulosclerosis. J Am Soc Nephrol 2012;23: 1351–63
- D' Agati VD. Pathobiology of focal segmental glomerulosclerosis: New developments. Curr Opin Nephrol Hypertens 2012;21: 243–50
- Schwartz MM. The role of podocyte injury in the pathogenesis of focal segmental glomerulosclerosis. Ren Fail 2000;22: 663–84
- Noel LH. Morphological features of primary focal and segmental glomerulosclerosis. Nephrol Dial Transplant 1999;14: 53–7
- Wang C, Li Y, Fan J. Relationship between the number of podocytes in glomerulus and the clinical manifestations and renal pathological features in IgA nephropathy. Presented at48th Congress of the European Renal Association and European Dialysis and Transplant Association 2011 , 23–6 Jun 2011, F-26
- Xu S, Xu G, Zeng L. Immunosuppressive treatment in primary focal segmental glomerulosclerosis. J Nephrol 2012; 25:626–35
- Wang X, Huang JP, Zhu BZ, et al. Clinicopathological feature and treatment of idiopathic membranous nephropathy in children. ZhonghuaErKe ZaZhi 2011;49: 311–5
- Gbadegesin R, Lavin P, Foreman J, Winn M. Pathogenesis and therapy of focal segmental glomerulosclerosis: An update. PediatrNephrol 2011;26: 1001–15
- Meyrier AY. Treatment of focal segmental glomerulosclerosis with immunophilin modulation: When did we stop thinking about pathogenesis? Kidney Int 2009;76: 487–91
- Meyrier A. An update on the treatment options for focal segmental glomerulosclerosis. Expert Opin Pharmacother 2009;10: 615–28
- Savin VJ, McCarthy ET, Sharma M. Permeability factors in focal segmental glomerulosclerosis. Semin Nephrol 2003;23: 147–60
- Daskalakis N, Winn MP. Focal and segmental glomerulosclerosis: Varying biologic mechanisms underlie a final histopathologic end point. Semin Nephrol 2006;26: 89–94
- Barisoni L, Kriz W, Mundel P, D'Agati V. The dysregulated podocyte phenotype: A novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 1999;10: 51–61
- Schwimmer JA, Markowitz GS, Valeri A, Appel GB. Collapsing glomerulopathy. Semin Nephrol 2003;23: 209–18
- Kriz W. The pathogenesis of “classic” focal segmental glomerulosclerosis—Lessons from rat models. Nephrol Dial Transplant 2003;18: vi39–44